Advertisement


Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Advertisement